Cardiac Myosin-Binding Protein C as a New Biomarker in the Diagnosis of Myocardial Infarction

Myocardial infarction is an emergency situation, and its early diagnosis is vital for patients and for the treatment which will be followed. Till now the diagnosis of myocardial infarction is based on the increased cardiac troponins I and T in the patient's serum, these biomarkers are the gold standard for the diagnosis of myocardial infarction but there are some limitations due to their slow release from the damaged myocytes. For this reason, new biomarkers are needed to be used for a faster diagnosis. New biomarkers should increase rapidly after acute myocardial infarction and should have cardiac selectivity. Myosin-binding protein C is a newly described candidate biomarker of cardiac injury and in small studies, it appears that its serum concentration decreases and increases faster than that of the troponin T and I. 
Cardiac troponins are released and cleared slowly after myocardial injury, complicating the diagnosis of an early and recurrent, acute myocardial infarction. Cardiac myosin-binding protein C is a similar cardiac protein that may have different release/clearance kinetics.